For healthcare professionals only.

EU Summary of Product
Characteristics for REVLIMID

Ready
to learn
more
about
proven
survival
in newly
diagnosed
TNE MM?

MM=multiple myeloma; TNE=transplant non-eligible.

triplet for NDMM*

03/19 INT-REV190006

Indication
REVLIMID as combination therapy
with dexamethasone, or bortezomib
and dexamethasone, or melphalan
and prednisone (see section 4.2) is
indicated for the treatment of adult
patients with previously untreated
multiple myeloma who are not
eligible for transplant.

*REVLIMID+bortezomib+
dexamethasone.
NDMM=newly diagnosed multiple myeloma.